Will a new weight-loss drug mess with your coffee or antidepressants? a new study aims to find out.
NCT ID NCT06564441
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This completed Phase 1 trial looked at whether multiple doses of Survodutide, a weight-loss drug, change how the body absorbs and processes three common drugs: bupropion (an antidepressant), caffeine, and midazolam (a sedative). Thirty-four otherwise healthy adults with overweight or obesity took these drugs alone and then again while on Survodutide. Researchers measured drug levels in the blood to see if Survodutide interferes with them. The goal is to understand potential drug interactions for future safe use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
SGS Life Science Services - Clinical Research
Edegem, 2650, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Survodutide (also known as BI 456906), bupropion, caffeine, midazolam
What this could lead to
If successful, this study could help doctors understand whether Survodutide changes how other drugs work in the body, guiding safer use in people with overweight or obesity.
What could go wrong
This is an early Phase 1 trial with only 34 participants, so results may not apply to everyone. The study focuses on drug interactions, not on treating obesity or related conditions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.